



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2184049 C 2007/10/02

(11)(21) **2 184 049**

(12) **BREVET CANADIEN  
CANADIAN PATENT**

(13) **C**

(22) Date de dépôt/Filing Date: 1996/08/23  
(41) Mise à la disp. pub./Open to Public Insp.: 1997/02/27  
(45) Date de délivrance/Issue Date: 2007/10/02  
(30) Priorité/Priority: 1995/08/26 (DE195 31 464.6)

(51) Cl.Int./Int.Cl. *C07D 207/12* (2006.01),  
*A61K 31/40* (2006.01)

(72) Inventeurs/Inventors:  
STEIN, INGE, DE;  
BEERES, HOLGER, DE;  
BESCHMANN, KLAUS, DE;  
NEUENFELD, STEFFEN, DE;  
BARBER, ANDREW, DE

(73) Propriétaire/Owner:  
TIOGA PHARMACEUTICALS, INC., US

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : MODIFICATION CRISTALLINE THERMIQUEMENT STABLE AU STOCKAGE DE N-METHYL-N-[(1S)-1-PHENYL-2-((3S)-3-HYDROXY-PYRROLIDIN-1-YL)ETHYL]-2,2-DIPHENYLACETAMIDE ET SON PROCEDE DE PREPARATION

(54) Title: THERMALLY STABLE STORABLE CRYSTALLINE MODIFICATION OF N-METHYL-N-[(1S)-1-PHENYL-2-((3S)-3-HYDROXY-PYRROLIDIN-1-YL)ETHYL]-2,2-DIPHENYLACETAMIDE AND A PROCESS FOR ITS PREPARATION

(57) **Abrégé/Abstract:**

The invention relates to a novel heat-stable form of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and to a process for the preparation and isolation of this compound in this novel form, and to use for the production of medicaments which contain this compound and/or one of its physiologically acceptable salts.



2184049

Abstract

The invention relates to a novel heat-stable form of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and to a process for the preparation and isolation of this compound in this novel form, and to use for the production of medicaments which contain this compound and/or one of its physiologically acceptable salts.

31104-1

- 1 -

THERMALLY STABLE STORABLE CRYSTALLINE MODIFICATION  
OF N-METHYL-N-[(1S)-1-PHENYL-2-((3S)-3-HYDROXY-  
PYRROLIDIN-1-YL)ETHYL]-2,2-DIPHENYLACETAMIDE  
AND A PROCESS FOR ITS PREPARATION

The present invention relates to a novel heat-stable form of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and to a process for the preparation and isolation of this compound in this novel form, and to use for the production of medicaments which contain this compound and/or one of its physiologically acceptable salts.

Compounds of this structural formula and also the abovementioned compound and suitable processes for their preparation are described in Published German Patent Application DE 42 15 213 A1.

It has been found that the compound N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, which is already known from Patent Application DE 42 15 213 A1, is a pharmaceutically particularly active compound which is very particularly suitable as a medicament for the treatment of inflammatory bowel disorders. In particular, this compound can be employed and is effective in this indication, as it simultaneously alleviates the pain associated with this disorder and in the acute case of an intestinal occlusion threatening or produced by the inflammatory bowel disorder again normalizes the motoricity of the intestine or sets it in motion again without causing noticeable side effects.

Attempts to prepare [lacuna] according to the process known from DE 42 15 213 A1 have shown that this compound is obtained in various forms.

It was therefore the object of the invention to make available N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide in heat-stable form and to provide a process for the preparation of this compound, by means of which a heat-stable product is obtained which is stable on storage and suitable for the production of pharmaceutical formulations.

30468-7

- 2 -

The invention thus relates to heat-stable, storable N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and to its use as a medicament for the treatment of inflammatory  
5 bowel disorders and also to pharmaceutical preparations which contain this compound as a constituent and can therefore be employed for the effective treatment of inflammatory bowel disorders and the disease symptoms associated therewith, and for the treatment of severe pain,  
10 in particular of hypersensitivity to pain.

The invention likewise relates to the use of this compound as a medicament for the treatment of pain and hypersensitivity to pain occurring in back complaints, burn injuries, sunburn and rheumatic disorders, and also  
15 inflammatory reactions occurring in this context. The invention also relates to the use of this medicament for the treatment of post-operative pain, hypersensitivity reactions to pain, and the ileus frequently occurring after abdominal operations. The invention further relates to the use of the  
20 corresponding compound in pharmaceutical formulations for the treatment of neurodermatitis.

This invention moreover relates to a process for the preparation of heat-stable, storable N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-  
25 diphenylacetamide.

According to one aspect of the present invention, there is provided N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride in a thermodynamically stable crystal modified  
30 form having a melting point of 220-225°C.



30468-7

- 2a -

According to another aspect of the present invention, there is provided use of the compound as described herein in production of a pharmaceutical formulation with pharmacological action as a kappa-opiate  
5 agonist.

According to still another aspect of the present invention, there is provided use of the compound as described herein in production of a pharmaceutical formulation for treatment of an inflammatory bowel disorder.

10 According to yet another aspect of the present invention, there is provided use of the compound as described herein in production of a pharmaceutical formulation for treatment of pain or a hypersensitivity to pain occurring in a back condition.

15 According to a further aspect of the present invention, there is provided use of the compound as described herein in production of a pharmaceutical formulation for treatment of one or more of pain,  
hypersensitivity to pain and inflammatory reactions in one  
20 or more conditions selected from rheumatic disorders, burn injuries, sunburn and neurodermatitis.

According to yet a further aspect of the present invention, there is provided use of the compound as described herein in production of a pharmaceutical  
25 formulation for treatment of one or more conditions selected from postoperative pain, hypersensitivity to pain and postoperative ileus.

According to still a further aspect of the present invention, there is provided a process for preparation of  
30 N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride, wherein

30468-7

- 2b -

1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methyl-amino-2-phenylethane and diphenylacetyl chloride are reacted with one another at a temperature of -5 to 10°C by slowly adding the diphenylacetyl chloride dissolved in a solvent to the  
5 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane dissolved in the same solvent and initially introduced into an apparatus while maintaining the temperature, and, following the reaction, the crude product obtained is recrystallized from a solvent.

10           The compound according to the invention and its physiologically acceptable salts exhibit particularly good analgesic actions. In this connection, they antagonize, in particular, inflammation-related hyperalgesias, but are also effective in the control of the actual inflammatory event,  
15 so that they have a broad spectrum of action.

          Experiments have shown that the compound according to the invention is active in the "writhing test" on mice or rats (method cf. Siegmund et al., Proc. Soc. Exp. Biol. 95, (1957), 729-731). The analgesic action as such can be  
20 further demonstrated in the "tail-flick test" on mice or rats (methodology cf. d'Amour and Smith, J. Pharmacol. Exp. Ther. 72, (1941), 74-79) and further in

the "hot plate test" (cf. Schmauss and Yaksh, J. Pharmacol. Exp. Ther. 228, (1984), 1-12 and the literature cited there). Particularly strong actions are to be observed on rats in the carrageenan-induced hyperalgesia model (cf. Bartoszyk and Wild, Neuroscience Letters 101 (1989) 95). In this context, this compound shows no or only a small tendency to physical dependence.

Additionally, by means of corresponding experiments carried out by familiar methods, pronounced anti-inflammatory, diuretic, anticonvulsive and neuroprotective actions were demonstrated. The compound exhibits a high affinity with respect to the binding behaviour to kappa-receptors.

In contrast to other compounds having a similar spectrum of action, the compound according to the invention is particularly suitable for use in pharmaceutical preparations for the treatment of inflammatory bowel disorders, as in addition to the analgesic and anti-inflammatory action it is suitable for normalizing disorders of the intestinal motoricity produced by the disorder. In particular, it is suitable for getting the bowel movements going again if, due to the inflammatory bowel disorder, intestinal obstruction threatens or has already occurred. This action can also be employed for the treatment of postoperative ileus and the pain associated therewith.

On account of the pharmacological activity described above, the compound according to the invention has proved particularly suitable in the treatment of burns, namely both of burns due to the action of heat or flames and also of severe sunburn. In particular, in addition to the actual pain and hypersensitivity reactions to pain, inflammatory processes can additionally be influenced in these indications by the administration of suitable pharmaceutical preparations which comprise the active compound according to the invention. Also, the reflex ileus occurring in the case of the most severe burns can be prevented or treated.

In this connection, indications have also been



found which point to an advantageous action in the treatment of allergies to the sun, especially as under the influence of the compound according to the invention allergic skin reactions rapidly fade and the itching associated therewith rapidly subsides. Corresponding positive results were also found in the treatment of neurodermatitis. In particular, the itching of the skin in this disorder subsides under the action of the above-mentioned active compound and inflammatory reactions occurring due to the disorder are favourably influenced.

Furthermore, this active compound has proved particularly effective in the treatment of rheumatic disorders and of back conditions. It is particularly advantageous in this connection that it is both active against the pain associated therewith and positively affects the inflammatory processes occurring in rheumatic disorders and thus contributes to an improvement in the general condition of the patient. In this context, it has advantageously been shown that normal motoricity of the gastrointestinal tract is not adversely affected.

In all indication areas described here, the use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride as a medicament has emerged as particularly effective in all sorts of preparation forms.

Chemical and physical investigations for the characterization of this compound according to the invention have shown that it is contained in various forms, depending on preparation and storage.

In detail, to date four different forms have been found, which differ from one another significantly. Type I is a solvate. This form is readily converted into another crystal type, which is designated in the following text as type II. On slow heating of type I a release of solvent takes place. The X-ray diffractometry, IR analysis and the melting point data then correspond to those of type II.

The compound prepared by the previously known process described in the earlier application



DE 4215 213 A1 is obtained as type II and has a melting range of 196-200°C (see also Bioorganic & Medicinal Chemistry Letters 4 (5), 679 (1994) and has a heat of fusion of 100 J/g.

5           A form designated as type III is obtained if type II is stored under extreme conditions at an atmospheric humidity of approximately 73 to 95%.

          A modification characterized in the following as type IV has, compared with that of type II, a melting  
10       range of approximately 220-226°C and a heat of fusion of approximately 120-128 J/g.

          The higher melting point and the higher heat of fusion of the compound according to the invention show that the thermodynamically stable crystal modification is  
15       present, the two crystal modifications II and IV obtained being monotropic to one another.

          This state of affairs can be confirmed by further observations. On very rapid cooling of a melt obtained from the thermodynamically unstable crystal modification  
20       (m.p. 196-200°C) from 210°C to -78°C and storage at -78°C for 5 hours the thermostable compound (221-226°C) slowly crystallizes out.

          In the case of these two types, not only their melting behaviour differs. They also differ in their  
25       storage stabilities. After storage of type II in a drying oven at 170°C a partial conversion into type IV was detected. During DSC determination (DSC = Differential Scanning Calorimetry) of the crystal modification of type II, on slow heating above the melting point at  
30       approximately 200°C, the crystal type IV which melts at approximately 220-226°C crystallizes out. Crystal type IV is also detected when a melt of type II (just above 200°C) is suddenly cooled and stored at room temperature for a period of 12 to 16 hours. While type II has  
35       therefore proved to be metastable, type IV is the thermodynamically stable modification. By means of specific crystallization tests, it was found that by addition of seed crystals of type IV only the crystal modification IV is obtained. In contrast to this,

however, by seeding with seed crystals of type II the crystal modification IV is especially obtained. Additionally, the solubility of the crystal type IV in aqueous solution is lower than that of type II. It is approximately 45 to 70% of the solubility of type II.

After seven months' storage of the compound prepared by the process described in the earlier application DE 4515213 A1 at room temperature, it was possible to determine a start of conversion to the thermostable crystal modification IV. That is to say, the compound prepared by the process described in this invention is stable on storage in contrast to the other crystal modification.

In the presence of solvents (e.g. water), the compound prepared can form solvates.

When using the compound according to the invention with the crystal modification of the type II in pharmaceutical formulations, on relatively long storage a change in the crystal modifications can occur.

Previous investigations of the pharmaceutical activity have so far shown it to be relatively independent of the crystal modification, which, however, does not exclude differences due to a possibly modified bioavailability. For use in solid pharmaceutical formulations, care must therefore be taken that the stable crystal modification of the type IV is employed, or that when using the type II additives are employed by means of which a long-term stabilization of this crystal type is effected.

Surprisingly, it now appeared that not only the manner of working up of the crude product obtained by the actual reaction has an influence on the crystal modification, but that even the conditions under which the starting materials react with one another are important for this. It was found that in this case, in particular, the reaction temperatures and the solvent conditions play a part.

In detail, it has been shown that the crystallization type IV is obtained if the reaction of the

starting materials 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane and diphenylacetyl chloride is carried out at low temperatures, in particular at -5 to 10°C, preferably at 0 to 8°C.

5           It has furthermore proved advantageous for this purpose that the molar ratio of the starting materials 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane and diphenylacetyl chloride to one another is 1:0.75 to 1:1.65, preferably 1:1.1 to 1:1.3.

10           The molar ratio of the starting compounds 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane and diphenylacetyl chloride to the solvent used should in this case be selected such that the starting materials are in solution, but the solvent if  
15 possible is present only in a small excess. If tetrahydrofuran is selected as a solvent, it has proved advantageous if the molar ratio of the abovementioned starting materials and the solvent to one another is approximately (0.8-1.2):(0.9-1.3):(14-22). A ratio of  
20 (0.9-1.1):(1-1.2):(16-19) has proved particularly effective.

A very slow addition of the diphenylacetyl chloride dissolved in one part of the solvent used has proved particularly advantageous, namely in particular  
25 while maintaining a low temperature. To complete the reaction, stirring is continued for some time at the same temperature, but if possible for not longer than approximately 4 hours. A period of stirring of 1.5 to 2.5 hours has emerged as optimum.

30           To purify the crude product obtained in this manner, it is recrystallized from a suitable solvent. In this context it is advantageous to select the amount of solvent such that the product crystallizes even in the hot solvent.

35           When using ethanol, this is achieved at molar ratios of approximately one mol of product relative to 75 to 125 mol, in particular 85 to 115 mol, of solvent.

Depending on the choice of the solvent from which it is recrystallized, the purified product is



precipitated in crystalline form in the modification of the type IV even after brief cooling. When using ethanol, it is the case after cooling to temperatures of approximately 55 to 45°C. It has proved advantageous in this case to maintain this temperature during the entire crystallization.

It has proved particularly advantageous in the case of the compound according to the invention that it obviously cannot pass through the blood-brain barrier on account of its structure and therefore exhibits no dependence potential. Also, until now no side effects have been found which would restrict the use of the advantageous actions for the claimed indications in any way.

The compound according to the invention and its physiologically acceptable salts can therefore be used for the production of pharmaceutical preparations by bringing them into the suitable dose form together with at least one excipient or auxiliary and, if desired, with one or more further active compounds. The preparations thus obtained can be employed as medicaments in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for enteral (e.g. oral or rectal) or parenteral administration and do not react with the novel compound, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, glycerol triacetate and other fatty acid glycerides, gelatin, soya lecithin, carbohydrates such as lactose or starch, magnesium stearate, talc or cellulose.

For oral administration, in particular tablets, coated tablets, capsules, syrups, juices or drops are used. Of interest are especially coated tablets and capsules having enteric coatings or capsule shells. For rectal administration, suppositories are used, and for parenteral administration, solutions, preferably oily or aqueous solutions, and also suspensions, emulsions or implants are used.

The active compound claimed according to the invention can also be lyophilized and the lyophilizate

obtained used, for example, for the production of injection preparations.

5 The preparations indicated can be sterilized and/or contain auxiliaries such as preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants and/or flavourings. If desired, they can also contain one or more further active compounds, e.g. one or more vitamins, diuretics or antiinflammatories.

10 The compound I according to the invention is generally administered in analogy to other known preparations available commercially for the indications claimed, preferably in doses of between about 1 mg and 50 mg, in particular between 5 and 30 mg, per dose unit. The daily  
15 dose is preferably between about 0.02 and 20 mg/kg, in particular 0.2 and 0.4 mg/kg of body weight.

The specific dose for each individual patient depends, however, on all sorts of factors, for example on the age, body weight, general state of health and sex,  
20 on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy applies. Oral administration is preferred.

In the following, examples are given which serve  
25 to illustrate the invention, but do not restrict the invention to the examples given.

In the following text all temperatures are indicated in °C.

#### Comparison Example

30 N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride (type II)

22 g of 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane are initially introduced into a 500 ml apparatus and dissolved in 150 ml of tetrahydro-  
35 furan. While stirring, a solution consisting of 150 ml of tetrahydrofuran and 24.1 g of diphenylacetyl chloride is added dropwise at 10-20°C in the course of one hour, a precipitate being formed at the start which, however,

goes into solution again in the course of the reaction. Towards the end of the reaction a precipitate is again formed. The mixture is stirred at room temperature for a further 12 hours. It is then cooled to about 5°C and the precipitated product is filtered off with suction. The separated product is washed with about 100 ml of tetrahydrofuran and dried. In this way, 39 g of crude product are obtained. This is recrystallized using about 250 ml of ethanol and 1 g of active carbon.

Yield: 33 g of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride (73.2% of theory)

Melting point: 196-200°C

Heat of fusion: 100 J/g

pK<sub>a</sub>: 7.4

Solubility in water at 20°C: 1.16 g/100 ml

Solubility in methanol at 20°C: 6.31 g/100 ml

#### Example 1

N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride (type IV)

A solution consisting of 10.5 g of diphenylacetyl chloride and 17 ml of tetrahydrofuran is slowly added dropwise with stirring in the course of 75 minutes to a reaction solution, cooled to 0 to 8°C, consisting of 9 g of 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane and 40 ml of tetrahydrofuran. The mixture is then stirred at the same temperature for a further 120°C [sic]. The reaction product depositing in the course of this as a precipitate is filtered off with suction and dried. In this manner 17 g of crude product are obtained, which are recrystallized from 180 ml of ethanol. During this recrystallization, the product prepared is deposited at 50°C as the stable crystal type IV.

Yield: 13 g of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride (70.6% of theory)

Melting point: 220-225°C

Heat of fusion: 124 J/g



pK<sub>a</sub>: 7.4

Solubility in water at 20°C: 0.76 g/100 ml

Solubility in methanol at 20°C: 4.26 g/100 ml

5 The following examples relate to pharmaceutical preparations:

Example A: Injection vials

10 A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate are adjusted to pH 6.5 in 3 l of double-distilled water using 2N hydrochloric acid, sterile filtered, filled into injection vials, lyophilized under sterile conditions and aseptically sealed. Each injection vial contains 5 mg of active compound.

Example B: Suppositories

15 A mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.

Example C: Solution

20 A solution is prepared from 1 g of an active compound of the formula I, 9.38 g of NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, 28.48 g of Na<sub>2</sub>HPO<sub>4</sub>·12H<sub>2</sub>O and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The solution is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation.

Example D: Ointment

500 mg of an active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.

30 Example E: Tablets

A mixture of 1 kg of active compound, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets in such a way that each tablet contains 10 mg of active compound.

Example F: Coated tablets

Analogously to Example E, tablets are pressed which are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and

colourant.

Example G: Capsules

2 kg of active compound are filled into hard  
gelatin capsules in the customary manner such that each  
5 capsule contains 20 mg of the active compound.

Example H: Ampoules

A solution of 1 kg of active compound in 60 l of  
double-distilled water is sterile filtered, filled into  
ampoules, lyophilized under sterile conditions and  
10 aseptically sealed. Each ampoule contains 10 mg of active  
compound.

31104-1

- 13 -

CLAIMS:

1. N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride in a thermodynamically stable crystal modified  
5 form having a melting point of 220-225°C.
2. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
3. Use of the compound according to claim 1 in  
10 production of a pharmaceutical formulation with pharmacological action as a kappa-opiate agonist.
4. Use of the compound according to claim 1 in production of a pharmaceutical formulation for treatment of an inflammatory bowel disorder.
- 15 5. Use of the compound according to claim 1 in production of a pharmaceutical formulation for treatment of pain or a hypersensitivity to pain occurring in a back condition.
- 20 6. Use of the compound according to claim 1 in production of a pharmaceutical formulation for treatment of one or more of pain, hypersensitivity to pain and inflammatory reactions in one or more conditions selected from rheumatic disorders, burn injuries, sunburn and neurodermatitis.
- 25 7. Use of the compound according to claim 1 in production of a pharmaceutical formulation for treatment of one or more conditions selected from postoperative pain, hypersensitivity to pain and postoperative ileus.



31104-1

- 14 -

8. Use of the compound according to claim 1 as a kappa-opiate agonist.

9. Use of the compound according to claim 1 for treatment of an inflammatory bowel disorder.

5 10. Use of the compound according to claim 1 for treatment of pain or a hypersensitivity to pain occurring in a back condition.

11. Use of the compound according to claim 1 for treatment of one or more of pain, hypersensitivity to pain  
10 and inflammatory reactions in one or more conditions selected from rheumatic disorders, burn injuries, sunburn and neurodermatitis.

12. Use of the compound according to claim 1 for treatment of one or more conditions selected from  
15 postoperative pain, hypersensitivity to pain and postoperative ileus.

13. The compound according to claim 1 for treatment of an inflammatory bowel disorder.

14. The compound according to claim 1 for treatment of  
20 pain or a hypersensitivity to pain occurring in a back condition.

15. The compound according to claim 1 for treatment of one or more of pain, hypersensitivity to pain and inflammatory reactions in one or more conditions selected  
25 from rheumatic disorders, burn injuries, sunburn and neurodermatitis.

16. The compound according to claim 1 for treatment of one or more conditions selected from postoperative pain, hypersensitivity to pain and postoperative ileus.

30468-7

- 15 -

17. The pharmaceutical composition according to claim 2, with pharmaceutical action as a kappa-opiate agonist.

18. The pharmaceutical composition according to  
5 claim 2 for treatment of an inflammatory bowel disorder.

19. The pharmaceutical composition according to claim 2 for treatment of pain or hypersensitivity to pain occurring in a back condition.

20. The pharmaceutical composition according to  
10 claim 2 for treatment of one or more of pain, hypersensitivity to pain and inflammatory reactions in one or more conditions selected from rheumatic disorders, burn injuries, sunburn and neurodermatitis.

21. The pharmaceutical composition according to  
15 claim 2 for treatment of one or more conditions selected from postoperative pain, hypersensitivity to pain and postoperative ileus.

22. A process for preparation of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride, wherein 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methyl-amino-2-phenylethane and diphenylacetyl chloride are reacted with one another at a temperature of -5 to 10°C by slowly adding the diphenylacetyl chloride dissolved in a solvent to the  
20 1-[(1S)-3-hydroxypyrrolidin-1-yl]-(2S)-2-methylamino-2-phenylethane dissolved in the same solvent and initially introduced into an apparatus while maintaining the temperature, and, following the reaction, the crude product obtained is recrystallized from a solvent.